Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Boston Scientific (NYSE:BSX) had its target price upped by equities research analysts at Robert W. Baird from $50.00 to $51.00 in a research note issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the medical equipment provider’s stock. Robert W. Baird‘s price objective would suggest a potential upside of 21.16% from the stock’s previous close.

Several other research analysts have also issued reports on the company. Citigroup decreased their target price on Boston Scientific from $50.00 to $48.00 and set a “neutral” rating for the company in a research report on Monday, October 5th. Leerink Partners dropped their price target on Boston Scientific from $60.00 to $55.00 and set an “outperform” rating on the stock in a research report on Friday, October 9th. TD Cowen reaffirmed a “buy” rating and issued a $56.00 price target (down from $61.00) on shares of Boston Scientific in a research note on Tuesday, October 20th. Truist Financial decreased their price objective on Boston Scientific from $57.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Finally, Canaccord Genuity Group set a $48.00 price objective on Boston Scientific in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $63.77.

Boston Scientific Trading Down 6.6%

Shares of BSX opened at $42.09 on Thursday. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $45.12 and its 200-day moving average price is $57.43. The firm has a market capitalization of $61.00 billion, a price-to-earnings ratio of 17.04, a PEG ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the prior year, the firm earned $0.75 earnings per share. Boston Scientific’s revenue was up 1.4% on a year-over-year basis. Sell-side analysts anticipate that Boston Scientific will post 3.21 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, Director David Habiger purchased 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, with a total value of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward Ludwig acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BSX. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Boston Scientific in the third quarter worth approximately $17,463,000. Vise Technologies Inc. lifted its holdings in shares of Boston Scientific by 22.6% during the 3rd quarter. Vise Technologies Inc. now owns 35,744 shares of the medical equipment provider’s stock valued at $1,560,000 after buying an additional 6,585 shares during the period. Cidel Asset Management Inc. bought a new position in shares of Boston Scientific during the 3rd quarter valued at $212,000. MGO One Seven LLC boosted its stake in shares of Boston Scientific by 1.9% in the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after buying an additional 260 shares during the last quarter. Finally, Americana Partners LLC purchased a new position in shares of Boston Scientific in the 3rd quarter worth $740,000. 89.07% of the stock is owned by institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue rose 1.5% to $5.138 billion, exceeding analysts’ $5.07 billion estimate, while adjusted EPS of $0.73 matched expectations. Management also reaffirmed its long-term growth strategy and highlighted progress in clinical programs and FDA clearances. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management expects approximately 4% organic revenue growth for full-year 2026 and is targeting a recovery cycle after anticipated 2027 weakness, followed by expansion toward 2030. Recent insider activity also showed purchases rather than sales, including a substantial purchase by CEO Michael Mahoney. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Needham lowered its price target from $57 to $48 but maintained a Buy rating, while JPMorgan downgraded BSX from Overweight to Neutral and set a $46 target. The revised targets remain above the stock’s recent trading level but reflect reduced confidence in the near-term outlook.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations, customer activity, and the recovery timeline. Boston Scientific cut its full-year EPS outlook to $3.16–$3.18 and expects fourth-quarter reported and organic sales to decline 1%–3%. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand, pricing pressure in China, and management’s warning that 2027 could be difficult. GAAP EPS fell to $0.40 from $0.51 a year earlier, and the stock has traded near a four-year low.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.